Capricor Therapeutics Inc (CAPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) has a cash flow conversion efficiency ratio of -0.105x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.25 Million) by net assets ($278.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CAPR market cap for the company's overall valuation and market capitalisation.
Capricor Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Capricor Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Capricor Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Capricor Therapeutics Inc ranked by their cash flow conversion efficiency. Explore CAPR cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Bohui Chemical Technology
SHE:300839
|
-0.134x |
|
Basler Kantonalbank
SW:BSKP
|
0.028x |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
-0.018x |
|
eDreams Odigeo SA
MC:EDR
|
0.387x |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
-0.095x |
|
Hangzhou Chinastars Reflective Material Co.Ltd.
SHE:301077
|
N/A |
|
Chularat Hospital Public Company Limited
BK:CHG
|
0.032x |
|
Yantai Longyuan Power Tech
SHE:300105
|
0.094x |
Annual Cash Flow Conversion Efficiency for Capricor Therapeutics Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Capricor Therapeutics Inc from 1999 to 2025. View current stock price of Capricor Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.79 Million | $-69.81 Million | -0.228x | +16.97% |
| 2024-12-31 | $145.46 Million | $-40.00 Million | -0.275x | +75.72% |
| 2023-12-31 | $22.60 Million | $-25.60 Million | -1.133x | -371.49% |
| 2022-12-31 | $11.79 Million | $4.92 Million | 0.417x | +177.85% |
| 2021-12-31 | $31.37 Million | $-16.81 Million | -0.536x | -50.29% |
| 2020-12-31 | $28.20 Million | $-10.05 Million | -0.357x | +64.25% |
| 2019-12-31 | $6.84 Million | $-6.82 Million | -0.997x | +66.79% |
| 2018-12-31 | $4.62 Million | $-13.86 Million | -3.003x | -136.94% |
| 2017-12-31 | $11.23 Million | $-14.23 Million | -1.268x | -132.11% |
| 2016-12-31 | $-4.00 Million | $-15.80 Million | 3.947x | -62.35% |
| 2015-12-31 | $-1.03 Million | $-10.82 Million | 10.484x | +6934.47% |
| 2014-12-31 | $-6.25 Million | $958.56K | -0.153x | -101.34% |
| 2013-12-31 | $-534.88K | $-6.14 Million | 11.487x | +2671.04% |
| 2012-12-31 | $4.89 Million | $-2.19 Million | -0.447x | +92.02% |
| 2011-12-31 | $830.72K | $-4.65 Million | -5.597x | -236.57% |
| 2010-12-31 | $2.60 Million | $-4.32 Million | -1.663x | +14.43% |
| 2009-12-31 | $2.98 Million | $-5.80 Million | -1.943x | +6.78% |
| 2008-12-31 | $5.10 Million | $-10.64 Million | -2.085x | -489.82% |
| 2007-12-31 | $15.20 Million | $-5.37 Million | -0.353x | -183.02% |
| 2006-12-31 | $-130.58K | $-55.60K | 0.426x | +85.78% |
| 2005-12-31 | $-77.62K | $-17.79K | 0.229x | -13.00% |
| 2004-12-31 | $-58.76K | $-15.48K | 0.263x | -48.52% |
| 2003-12-31 | $-40.69K | $-20.82K | 0.512x | -12.35% |
| 2002-12-31 | $-24.53K | $-14.32K | 0.584x | -59.91% |
| 2001-12-31 | $-8.94K | $-13.02K | 1.456x | +152.13% |
| 2000-12-31 | $13.36K | $-37.32K | -2.793x | -291.50% |
| 1999-12-31 | $-617.00 | $-900.00 | 1.459x | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more